Longitudinal evaluation of SNOT-22 can distinguish patients with chronic rhinosinusitis with nasal polyps who respond quickly ...

On a 5-point Likert scale, AI responses scored a 4.2 on both quality and empathy compared with scores of 3.0 on quality and 2 ...

Q1 2025 Earnings Call Transcript May 8, 2025 Insmed Incorporated misses on earnings expectations. Reported EPS is $-1.42 EPS, ...

Cancer related studies were among nearly 6,000 abstracts presented at Digestive Disease Week® (DDW) 2025, including research ...

Topical deep delivery of corticosteroids into the sinonasal cavity improves symptoms and sleep in patients with chronic rhinosinusitis.

Cases of pancreatic cancer have increased significantly among younger individuals compared with those aged 35 years and older ...

Chronic rhinosinusitis with nasal polyps (CRSwNP) inflammatory endotypes are associated with long-term air pollutant and allergen exposure.

Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) has demonstrated resilience amid recent financial challenges, with the stock experiencing a 34% increase over the last month. This notable price movement may ...

You’ve likely heard people mention that they have inherited certain health conditions from their family. These are known as ...

Operating profit / (loss): Operating profit was $10.6 million for the three months ended 31 March 2025, compared to ($48.4) ...

Learn more about whether Exact Sciences Corporation or Insmed Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.